Spyre Therapeutics
SYRE
107 hedge funds and large institutions have $1.18B invested in Spyre Therapeutics in 2024 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 47 increasing their positions, 17 reducing their positions, and 24 closing their positions.
176% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 17
74% more call options, than puts
Call options by funds: $61K | Put options by funds: $35K
21% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 24
9.65% more ownership
Funds ownership: 89.57% → 99.22% (+9.6%)
4% more funds holding
Funds holding: 103 → 107 (+4)
2% less capital invested
Capital invested by funds: $1.21B → $1.18B (-$29.2M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$123M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$67.4M |
| 3 |
BlackRock
New York
|
+$62.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$47.7M |
| 5 |
State Street
Boston,
Massachusetts
|
+$43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YF
Yu Fan
|
-$16.4M |
| 2 |
Millennium Management
New York
|
-$12.1M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$9.48M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$6.14M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$4.59M |
SYRE Hedge Fund Activity: Q2 2024 in Review
107 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q2 2024, worth a combined $1.18B — down 2.4% from $1.21B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new SYRE positions and 24 closed out — a net gain of 5 holders — while 47 added to existing stakes and 17 trimmed.
The largest buyer was Fairmount Funds Management, adding an estimated $123M. The largest seller was Yu Fan, exiting entirely with an estimated $16.4M sold.
- 107 institutional investors held Spyre Therapeutics (SYRE) as of Q2 2024, up from 103 in Q1 2024.
- Funds reported $1.18B of Spyre Therapeutics stock for Q2 2024, down 2.4% quarter-over-quarter.
- 29 funds opened new Spyre Therapeutics positions in Q2 2024 and 24 closed out, a net change of +5 holders.
- The largest Spyre Therapeutics buyer in Q2 2024 was Fairmount Funds Management, an estimated $123M added.
- The largest Spyre Therapeutics seller in Q2 2024 was Yu Fan, an estimated $16.4M sold.
Based on aggregated 13F filings for Q2 2024.